Status:
RECRUITING
Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment
Lead Sponsor:
Mario Steffanus
Collaborating Sponsors:
Dr Cipto Mangunkusumo General Hospital
Conditions:
Peptic Ulcer Bleeding
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to compare the effects of tegoprazan vs lansoprazole in healing bleeding peptic ulcers. It will also teach about the safety of both modalities. The main questions it...
Detailed Description
Peptic ulcer disease (PUD) is a condition characterized by disruption of the gastric and duodenal mucosal lining due to exposure to gastric acid or pepsin. Major causes include Helicobacter pylori inf...
Eligibility Criteria
Inclusion
- Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination
Exclusion
- Allergic to Tegoprazan or Lansoprazole
- Diagnosed with gastric or duodenal cancer, pregnant
- History of H. pylori infection treatment failure
- Presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis
- Alcohol consumption
- Undergoing chemotherapy
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT06894992
Start Date
May 1 2025
End Date
December 31 2025
Last Update
May 29 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cipto Mangunkusumo National General Hospital
Jakarta, DKI Jakarta, Indonesia, 10430
2
Atma Jaya Hospital
Jakarta, DKI Jakarta, Indonesia, 14440